Endo International PLC (NASDAQ:ENDP) shot up 2.9% on Wednesday . The company traded as high as $24.93 and last traded at $24.34, with a volume of 4,627,595 shares changing hands. The stock had previously closed at $23.66.

A number of brokerages have weighed in on ENDP. JMP Securities reaffirmed a “buy” rating and issued a $52.00 target price (down previously from $56.00) on shares of Endo International PLC in a report on Sunday, May 8th. Barclays PLC reissued a “hold” rating on shares of Endo International PLC in a report on Sunday, May 8th. Leerink Swann downgraded Endo International PLC from an “outperform” rating to a “market perform” rating and set a $23.00 price objective on the stock. in a report on Friday, May 6th. Deutsche Bank AG reissued a “buy” rating and set a $30.00 price objective on shares of Endo International PLC in a report on Wednesday, June 29th. Finally, BMO Capital Markets reissued a “hold” rating and set a $22.00 price objective on shares of Endo International PLC in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $39.78.

The stock’s market capitalization is $5.07 billion. The company’s 50 day moving average price is $19.23 and its 200 day moving average price is $25.92.

Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.12. During the same quarter in the previous year, the company earned $1.08 earnings per share. The business had revenue of $921 million for the quarter, compared to analysts’ expectations of $873.50 million. The business’s quarterly revenue was up 25.3% on a year-over-year basis. On average, equities research analysts anticipate that Endo International PLC will post $4.56 earnings per share for the current fiscal year.

A number of hedge funds have bought and sold shares of the stock. American International Group Inc. raised its stake in Endo International PLC by 21.8% in the fourth quarter. American International Group Inc. now owns 99,335 shares of the company’s stock valued at $6,081,000 after buying an additional 17,770 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares during the last quarter. Finally, RS Investment Management Co. LLC raised its stake in Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock valued at $33,279,000 after buying an additional 123,692 shares during the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.